Adoptive Cell Immunotherapy for Cancer
We are dedicated to research of cellular therapy for cancer with a focus on Adoptive T cell Transfer. The goal of our work is to produce antigen-specific T cells with desired functions and to produce them under conditions that would allow their use in clinics. The desired function of these T cells for cancer therapy should be their ability to eliminate cancer cells through recognition of multiple tumor-associated antigens (TAAs), migrate into tumors, and have the phenotype that would ensure their persistence after their transfer to the patient. Our studies are focused on prostate cancer and renal cell carcinoma.
Principal Investigator
Ph.D. Students
Undergraduate Students
Hana Svobodová, B.Sc.
Senior Scientists/Clinicians
prof. Jiřina Bartůňková, M.D., Ph.D., MBA
Current Grants
The Grant Agency of the Charles University, Czech Republic, No. 364218, Isolation, characterization and expansion of subsets of tumor-infiltrating lymphocytes of kidney cancer for the development of adoptive cell immunotherapy, 2018–2020
Charles University, No. PRIMUS/MED/12, Preparation of cytotoxic polyclonal T-cells for adoptive cellular immunotherapy of cancer, 2017–2019
- Ministry of Health of the Czech Republic, project AZV, No. 16-28135A, Preparation of polyclonal cancer-specific T-cells for adoptive cellular immunotherapy of prostate cancer, 2016–2019
